Hydrocephalus, also known as “water on the brain”, is a condition in which excess cerebrospinal fluid accumulates in the brain, leading to an enlargement of the ventricles. This accumulation of fluid can cause a wide range of neurological symptoms, including headaches, difficulty walking, and cognitive impairment. In severe cases, hydrocephalus can lead to blindness, coma, and even death. For many years, the primary treatment for hydrocephalus has been the surgical insertion of a shunt. This device is used to divert the excess fluid away from the brain and into another area of the body where it can be absorbed. While this treatment has been successful in many cases, it can also be associated with a number of risks and complications, including infection, blockage, and malfunction. In recent years, however, medical professionals have been exploring new treatment options for hydrocephalus that offer a more effective and less invasive alternative to traditional shunt surgery. In this article, we will explore these new treatments and discuss the potential benefits they offer for those living with hydrocephalus.
Endoscopic Third Ventriculostomy (ETV) is a minimally invasive procedure that is used to treat hydrocephalus. During the procedure, a small hole is created in the floor of the third ventricle, allowing the excess fluid to drain out of the brain and be absorbed into the body. This procedure has been found to be effective in treating hydrocephalus in some cases, and is associated with fewer risks and complications than traditional shunt surgery. One of the primary benefits of ETV is that it allows the patient to avoid the risks associated with shunt surgery, such as infection, blockage, and malfunction. Additionally, ETV can be performed in a shorter amount of time than shunt surgery, and the patient can typically return home the same day.
Stereotactic Ventriculocisternostomy (SV) is a newer procedure that is similar to ETV, but is performed using a special imaging technique known as stereotactic navigation. During the procedure, a small hole is created in the floor of the third ventricle, allowing the excess fluid to drain out of the brain and be absorbed into the body. Similar to ETV, SV is associated with fewer risks and complications than traditional shunt surgery. Additionally, it is less invasive and can be performed in a shorter amount of time than shunt surgery.
Ventriculoperitoneal shunting (VPS) is a procedure in which a tube is surgically inserted into the brain to drain excess fluid into the abdomen. This procedure is typically used in cases where ETV and SV are not appropriate or have failed. While VPS is associated with a number of risks and complications, it can be effective in treating hydrocephalus in some cases.
Hydrocephalus is a serious condition that can cause a wide range of neurological symptoms. For many years, the primary treatment for hydrocephalus has been the surgical insertion of a shunt. However, medical professionals have been exploring new treatment options for hydrocephalus that offer a more effective and less invasive alternative to traditional shunt surgery. Endoscopic Third Ventriculostomy (ETV), Stereotactic Ventriculocisternostomy (SV), and Ventriculoperitoneal Shunting (VPS) are three of the most commonly used treatments for hydrocephalus. Each of these procedures has its own set of risks and benefits, and it is important to discuss these with your doctor before deciding which treatment is right for you. With the right treatment, those living with hydrocephalus can experience an improved quality of life.
1.
Testosterone recovery linked to overall survival in high-risk prostate cancer
2.
Knowing about and avoiding bladder cancer.
3.
AI model combines clinical and magnetic resonance data to improve prediction of breast cancer recurrence
4.
How 7,000 steps a day could help reduce your risk of cancer
5.
ACS Guidelines Expand Lung Cancer Screening Eligibility -- Is That a Good Thing?
1.
Cancer Stem Cells: The Seeds of Tumorigenesis and Recurrence
2.
Clinical Analysis of Prostate Cancer
3.
Revolutionizing Cancer Care: The Impact of Darzalex Faspro
4.
Trends in Incidence, Care, and Surgery for Medullary Thyroid Cancer: A Review
5.
Exploring the Pleomorphic Adenoma: A Unique and Varied Tumor
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Targeting Oncologic Drivers with Dacomitinib: Further Discussion on Lung Cancer Treatment
2.
Efficient Management of First line ALK-rearranged NSCLC - Part VIII
3.
Navigating the Complexities of Ph Negative ALL - Part XII
4.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part III
5.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- The Conclusion
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation